drugset
drugset / Trial / NCT01501435

To Compare Safety and Pharmacokinetic Properties of CJ-30039 and Lipidil Supra

NCT01501435 ↗

Phase 1 Completed 48 enrolled HK inno.N Corporation
RandomizedCrossoverOpen-labelTreatment

Summary

To investigate the safety and pharmacokinetic properties of CJ-30039 and Lipidil Supra

Timeline

Start
2011-12
Primary completion
2012-04
Completion
2012-06

Drugs

EvaluationDrugModalityDoseRoute
Subject CJ-30039 Unknown — Oral
Comparator fenofibric acid Small molecule 160 mg Oral

Indications

No indication recorded.